Andexanet alfa (ONDEXXYA<sup>®</sup> for Intravenous Injection 200 mg), a reversal agent for direct factor Xa inhibitors: pharmacological characteristics and clinical evidence-Reference-Cited by-同舟云学术

Andexanet alfa (ONDEXXYA<sup>®</sup> for Intravenous Injection 200 mg), a reversal agent for direct factor Xa inhibitors: pharmacological characteristics and clinical evidence

Published:2023 Issue:1 Volume:158 Page:89-100
ISSN:0015-5691
Container-title:Folia Pharmacologica Japonica
language:en
Short-container-title:Folia Pharmacol. Jpn.

Author:

Yajima Toshitaka¹,Higashimori Mitsuo²,Takata Chie¹,Sasabe Toshikazu²

Affiliation:

1. Cardiovascular, Renal, and Metabolism, Medical Affairs, AstraZeneca K.K.

2. Data Science & Innovation Division, Research and Development, AstraZeneca K.K.

Publisher

Japanese Pharmacological Society

Subject

Pharmacology

Link

https://www.jstage.jst.go.jp/article/fpj/158/1/158_22107/_pdf

Reference23 articles.

1. 1) Connolly SJ, et al. N Engl J Med. 2009;361:1139-1151.

2. 2) Connolly SJ, et al. N Engl J Med. 2010;363:1875-1876.

3. 3) Granger CB, et al. N Engl J Med. 2011;365:981-992.

4. 4) Patel MR, et al. N Engl J Med. 2011;365:883-891.

5. 5) Giugliano RP, et al. N Engl J Med. 2013;369:2093-2104.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Facial trauma with life-threatening bleeding treated by andexanet alfa administration: A case report;Heliyon;2024-09

2. Acute Aortic Dissection Managed with Nafamostat for Heparin Resistance in the Presence of DOAC Reversal Agent: a Case Report;Japanese Journal of Cardiovascular Surgery;2024-05-15

3. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity: Prespecified Subgroup Analysis of the ANNEXA-4 Study in Japan;Journal of Atherosclerosis and Thrombosis;2023